Drugs / BL-B16D1
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06493864 | Aug 2024 → Jul 2026 overdue | breast cancer | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT06475131 | Jul 2024 → Jul 2026 overdue | neoplasm | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT06469008 | Jun 2024 → Jul 2026 overdue | head and neck squamous cell carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-05-10 | Sichuan Biokin Pharmaceutical Co., Ltd. | Regulatory 四川百利天恒药业股份有限公司自愿披露关于注射用BL-B16D1（双抗ADC）项目治疗晚期实体瘤获得I期临床试验批准通知书的公告 cninfo.com.cn ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-05-10 | Sichuan Biokin Pharmaceutical Co., Ltd. | 四川百利天恒药业股份有限公司自愿披露关于注射用BL-B16D1（双抗ADC）项目治疗晚期实体瘤获得I期临床试验批准通知书的公告 cninfo.com.cn ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BL-B16D1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06469008 ↗ |
| Route | Intravenous | “Administration by intravenous infusion for a cycle of 3 weeks.” NCT06469008 ↗ |